Product Name: KinSub1RRKSL
Product Number: PE-01AJG95
Size: | 200 µg | | Price: | 99.00 |
| | | $US | |
Peptide Name: KinSub1RRKSL
Product Use: For assaying the phosphotransferase activity of Interleukin-1 receptor-associated kinase-like 2 (IRAK2, UniProt ID O43187). The KinSub1RRKSL peptide demonstrated high phosphotransferase activity with CHK2, and exhibited moderate specificity when assayed with over 200 other protein kinases. A listing of other kinases that show appreciable phosphotransferase activity towards this peptide are listed in Table 1.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: KinSub1RRKSL was originally identified using a microarray with peptides that were predicted as optimal substrates for 500 human protein kinases with a proprietary algorithm developed at Kinexus with our academic partners.
Peptide Sequence: PGLSRRKSLRFKGGG
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1614.9 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Peptide Recommended Enzyme: CHK2
Scientific Background: Human IRAK2 is a protein-serine/threonine kinase of the TKL group of protein kinases in the IRAK family. This kinase is moderate to highly expressed in most tested human tissues. Orthologues of IRAK2 are highly conserved in vertebrates, including amphibians. IL1 stimulation leads to the formation of a signalling complex with IRAK2, which dissociates from the IL1 receptor (IL1RL1) following the binding of PELI1. IRAK2 is an important downstream signalling component of Toll-like receptors (TLRs) (1). IRAKs were first described as signal transducers for IL1 and later have been implicated in signal transduction of other members of the Toll/IL-1 receptor family. The interleukin-1 receptor (IL-1R) signalling pathway leads to NF_B activation in mammals. To date, four mammalian IRAKs have been identified (IRAK1, IRAK2, IRAK4, and IRAK-M) (2). It is believed that IRAK2 could be an additional therapeutic target for inhibiting IL1-induced inflammation. IRAK2 has also been linked with the development of lung adenocarcinomas.